IN2014DN07019A - - Google Patents

Info

Publication number
IN2014DN07019A
IN2014DN07019A IN7019DEN2014A IN2014DN07019A IN 2014DN07019 A IN2014DN07019 A IN 2014DN07019A IN 7019DEN2014 A IN7019DEN2014 A IN 7019DEN2014A IN 2014DN07019 A IN2014DN07019 A IN 2014DN07019A
Authority
IN
India
Prior art keywords
positive
methods
cancer
mammalian subject
diagnosing
Prior art date
Application number
Inventor
Hans Peter Gerber
Dena Marrinucci
Shepherd Steven Pirie
Eric Tucker
Original Assignee
Pfizer
Epic Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Epic Sciences Inc filed Critical Pfizer
Publication of IN2014DN07019A publication Critical patent/IN2014DN07019A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Methods are provided for detecting 5T4 positive circulating tumor cells in a mammalian subject. Methods of diagnosing 5T4 positive cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of 5T4 positive metastatic cancer or early stage 5T4 positive cancer.
IN7019DEN2014 2012-01-24 2013-01-22 IN2014DN07019A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261590066P 2012-01-24 2012-01-24
US201361753665P 2013-01-17 2013-01-17
PCT/IB2013/050547 WO2013111054A1 (en) 2012-01-24 2013-01-22 Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject

Publications (1)

Publication Number Publication Date
IN2014DN07019A true IN2014DN07019A (en) 2015-04-10

Family

ID=47844410

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7019DEN2014 IN2014DN07019A (en) 2012-01-24 2013-01-22

Country Status (15)

Country Link
US (1) US10254286B2 (en)
EP (1) EP2807485B1 (en)
JP (1) JP6254951B2 (en)
KR (1) KR101716555B1 (en)
CN (1) CN104094116B (en)
AU (2) AU2013213301A1 (en)
BR (1) BR112014018192A8 (en)
CA (1) CA2861437C (en)
ES (1) ES2724232T3 (en)
HK (1) HK1202923A1 (en)
IL (1) IL233543B (en)
IN (1) IN2014DN07019A (en)
MX (1) MX361058B (en)
RU (1) RU2646498C2 (en)
WO (1) WO2013111054A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2556639T3 (en) 2009-10-21 2016-01-19 The Scripps Research Institute Method for using non-rare cells to detect rare cells
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EA201691352A1 (en) * 2013-12-30 2016-11-30 Дзе Скриппс Рисерч Инститьют DIAGNOSIS OF LUNG CANCER BY CIRCULATING TUMOR CELLS
EP3100047B1 (en) 2014-01-27 2021-08-11 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
EA201691682A1 (en) 2014-02-21 2017-02-28 Эпик Сайенсиз, Инк. METHODS FOR ANALYZING RARE CIRCULATING CELLS IN THE BLOOD
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
EA201692223A1 (en) * 2014-05-09 2017-04-28 Дзе Скриппс Рисерч Инститьют COMPOSITIONS AND METHODS OF LIQUID BIOPSY OF MELANOMA
AU2015306692B2 (en) * 2014-08-25 2021-07-22 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
JP6815331B2 (en) * 2015-04-21 2021-01-20 ジェネンテック， インコーポレイテッド Compositions and Methods for Prostate Cancer Analysis
KR102045068B1 (en) * 2016-02-23 2019-11-15 노을 주식회사 Polymerase chain reaction patch, diagnostic method using the patch and device using the same
KR20170099739A (en) 2016-02-23 2017-09-01 노을 주식회사 Contact-type staining-assist patch, manufacturing method thereof and staining method using the patch
KR102406596B1 (en) * 2016-02-23 2022-06-10 노을 주식회사 Circulating tumor cell diagnosis method using the patch and device using the same
US10371610B2 (en) 2016-02-23 2019-08-06 Noul Co., Ltd. Contact-type patch, staining method using the same, and manufacturing method thereof
MA49289A (en) 2017-04-03 2020-02-12 Hoffmann La Roche ANTIBODIES BINDING TO STEAP-1
US20210018441A1 (en) * 2017-06-27 2021-01-21 Qcdx, Llc Quantitative liquid biopsy diagnostic system and methods
CN107918013A (en) * 2017-09-25 2018-04-17 浙江天科高新技术发展有限公司 The method and kit of K Ras albumen in chemiluminescence Enzyme immunoassay circulating tumor cell
JP2019195304A (en) 2018-05-10 2019-11-14 学校法人順天堂 Image analysis method, device, computer program, and generation method of deep learning algorithm
US20220002429A1 (en) * 2018-10-24 2022-01-06 Northwestern University Tumor cell aggregation inhibitors' for treating cancer
JP7381003B2 (en) * 2019-04-26 2023-11-15 学校法人順天堂 METHODS, APPARATUS AND COMPUTER PROGRAMS TO ASSIST DISEASE ANALYSIS AND METHODS, APPARATUS AND PROGRAMS FOR TRAINING COMPUTER ALGORITHM
US20230175073A1 (en) 2021-12-07 2023-06-08 Epic Sciences, Inc. Enhanced characterization of breast cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
EP0403559A1 (en) 1988-03-04 1990-12-27 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
IL132596A0 (en) 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
AU1290001A (en) 1999-11-18 2001-05-30 Oxford Biomedica (Uk) Limited Antibodies
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US7305112B2 (en) 2002-10-15 2007-12-04 The Scripps Research Institute Method of converting rare cell scanner image coordinates to microscope coordinates using reticle marks on a sample media
PE20060817A1 (en) * 2004-09-10 2006-10-10 Wyeth Corp HUMANIZED AND CONJUGATED ANTI-5T4 ANTIBODIES ANTI-5T4 / CALICHEAMICIN ANTIBODIES
US20090317836A1 (en) 2006-01-30 2009-12-24 The Scripps Research Institute Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject
MY148763A (en) 2006-03-10 2013-05-31 Wyeth Corp Anti-5t4 antibodies and uses thereof
WO2008131048A2 (en) 2007-04-16 2008-10-30 Cellpoint Diagnotics, Inc. Devices and methods for diagnosing, prognosing, or theranosing a condition by enriching rare cells
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
ES2557914T3 (en) 2009-03-24 2016-01-29 Biocept, Inc. Devices and methods of cell capture and analysis
ES2405605T3 (en) 2009-03-27 2013-05-31 Wyeth Llc Tumor-initiating cells and procedures for their use
EP2473619A4 (en) 2009-09-03 2013-03-27 Scripps Research Inst Method for categorizing circulating tumor cells
ES2556639T3 (en) 2009-10-21 2016-01-19 The Scripps Research Institute Method for using non-rare cells to detect rare cells
US9469876B2 (en) * 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
RU2550925C2 (en) 2010-07-07 2015-05-20 Зе Реджентс Оф Зе Юниверсити Оф Мичиган Diagnosing and treating breast cancer
KR101783529B1 (en) 2011-04-01 2017-09-29 와이어쓰 엘엘씨 Antibody-drug conjugates

Also Published As

Publication number Publication date
IL233543A0 (en) 2014-08-31
KR20140100580A (en) 2014-08-14
EP2807485A1 (en) 2014-12-03
AU2013213301A1 (en) 2014-07-17
CN104094116A (en) 2014-10-08
MX361058B (en) 2018-11-23
EP2807485B1 (en) 2019-03-13
CA2861437C (en) 2018-08-21
CN104094116B (en) 2017-05-31
AU2018220154A1 (en) 2018-09-13
JP6254951B2 (en) 2017-12-27
JP2015507190A (en) 2015-03-05
BR112014018192A8 (en) 2021-03-02
IL233543B (en) 2018-02-28
RU2014127474A (en) 2016-03-20
WO2013111054A1 (en) 2013-08-01
KR101716555B1 (en) 2017-03-14
US20150017661A1 (en) 2015-01-15
US10254286B2 (en) 2019-04-09
HK1202923A1 (en) 2015-10-09
CA2861437A1 (en) 2013-08-01
ES2724232T3 (en) 2019-09-09
MX2014008928A (en) 2014-10-24
RU2646498C2 (en) 2018-03-05

Similar Documents

Publication Publication Date Title
IN2014DN07019A (en)
EP2576837A4 (en) Prostate cancer associated circulating nucleic acid biomarkers
IL225646A0 (en) Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents
MX2013000917A (en) Methods of detecting diseases or conditions using phagocytic cells.
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
IL230687A0 (en) Methods for diagnosing cancer by characterization of tumor cells associated with pleural or serous fluids
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
EP2524059A4 (en) Detection of gastrointestinal disorders
EP2335075A4 (en) Methods for the detection of circulating tumor cells
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
GB2519906A (en) Methods and systems for detecting biological components
WO2007089911A3 (en) Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
MY170983A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
GB201015765D0 (en) Use of myeloid cell biomarkers for the diagnosis of cancer
MX2016012697A (en) Protein biomarker profiles for detecting colorectal tumors.
WO2013036543A3 (en) Molecular imaging of cancer cells in vivo
EP2971132A4 (en) Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer
EP3683321A3 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
NZ629555A (en) Monocyte biomarkers for cancer detection
EP2833149A4 (en) Method for detecting degree of malignancy of circulating tumor cell unit, and kit for same
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
EP3099821A4 (en) Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)
WO2013081645A3 (en) Erbb3 mutations in cancer